This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jun 20;28(18):2937-8.

doi: 10.1200/JCO.2010.29.3068. Epub 2010 May 10.

On target? Off target? Why we really do not know

Lawrence Leichman

PMID: 20458025
DOI: 10.1200/JCO.2010.29.3068

Editorial

On target? Off target? Why we really do not know

Lawrence Leichman. J Clin Oncol. 2010.

. 2010 Jun 20;28(18):2937-8.

doi: 10.1200/JCO.2010.29.3068. Epub 2010 May 10.

Author

Lawrence Leichman

PMID: 20458025
DOI: 10.1200/JCO.2010.29.3068

No abstract available

PubMed Disclaimer

Comment on

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Sun W, et al. J Clin Oncol. 2010 Jun 20;28(18):2947-51. doi: 10.1200/JCO.2009.27.7988. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458043 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.